share_log

太平洋4月9日发布研报称，给予福元医药（601089.SH）买入评级。评级理由主要包括：1）Q4收入增速放缓，集采影响有望2024年内出清；2）主营业务增速稳健，净利率持续改善；3）研发投入加大，在研品种储备丰富；4）分红比例提高，持续回馈投资者。（每日经济新闻）

Pacific released a research report on April 9 stating that it gave Fuyuan Pharmaceutical (601089.SH) a purchase rating. The main reasons for the rating include: 1) the growth rate of Q4 revenue is slowing, and the impact of collection is expected to be cl

Zhitong Finance ·  Apr 9 18:33
Pacific released a research report on April 9 stating that it gave Fuyuan Pharmaceutical (601089.SH) a purchase rating. The main reasons for the rating include: 1) the growth rate of Q4 revenue is slowing, and the impact of collection is expected to be cleared within 2024; 2) the growth rate of the main business is steady, and the net interest rate continues to improve; 3) the increase in R&D investment and abundant reserves of products under development; 4) the increase in the dividend ratio to continue to give back to investors. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment